Product Data Sheet

Product Name: THX-B
Cat. No.: GC67786

Chemical Properties

Cas. No.	1372206-64-8		
Formula	$C_{16}H_{24}N_6O_4$	M.Wt	364.4
Solubility	DMSO : 100 mg/mL (274.42 mM; Need ultrasonic)	Storage	4°C, protect from light
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	THX-B		

Background

THX-B is a potent and non-peptidic **$p75^{NTR}$** (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders[1][2][3].

THX-B (10 μM, 4 days) decreases proliferation of myoblasts[1].
THX-B (10 μM, 1 h) inhibits NGF-induced phosphorylation of ERK1/2 in C2C12 myoblasts[1].
THX-B (20 μM, 24 h) decreases photoreceptor cell death and reactive gliosis in cultured rd10 retinas[2].

Western Blot Analysis[1]

Cell Line: C2C12 myoblasts

Concentration: 10 μM

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Incubation Time:	Pre-treated for 1 hour
Result:	Inhibited βNGF-induced ERK2 phosphorylation by 67%.Inhibited proNGF-induced ERK2 phosphorylation by 90%.

Immunofluorescence[1]

Cell Line:	Cultured P22 rd10 retinas.
Concentration:	20 μM
Incubation Time:	24 h
Result:	Attenuated the thickening and enlargement of processes of astrocytes and MÜller glia cells.

THX-B (50 μg in 125 μL PBS, i.p. weekly for 4 weeks) improves bladder function in a mouse model of diabetic voiding dysfunction[3].
THX-B (2 μL of 2 μg/μL, IVT injection, a single dose) elicits a neuroprotective effect on photoreceptor cells in P17 rd10 mice[2].
THX-B (40 μg in 20 μL, IVT injection) resolves the inflammatory, vascular, and neurodegenerative phases of the retinal pathology[4].

Animal Model:	Mouse model of diabetic voiding dysfunction
Dosage:	50 μg in 125 μL PBS
Administration:	Intraperitoneal injection (i.p.)
Result:	Prevented bladder weight increase, which was 18% (95% CI 3%, 32%) and 37% (95% CI 14%, 60%) lower after 2 and 4 weeks of treatment.

Animal Model:	P17 rd10 mice[1]

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Dosage:	2 μL of 2 μg/μL, single dose
Administration:	Intravitreal (IVT) injected in one eye
Result:	Increased the number of photoreceptor rows as well as the ONL/INL ratio.Decreased the total number of microglial cells in the treated retinas, as well as some of the inflammatory signs, such as GFAP, α2M and the proinflammatory cytokines IL-1β and TNFα.

[1]. Keren Ettinger, et al. Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cell Signal. 2012 Dec;24(12):2378-88.
[2]. MarÍa PlatÓn-Corchado, et al. p75NTR antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa. Cell Death Dis. 2017 Jul 13;8(7):e2922.
[3]. Abubakr H Mossa, et al. Antagonism of proNGF or its receptor p75 NTR reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction. Diabetologia. 2020 Sep;63(9):1932-1946.
[4]. Alba Galan, et al. Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2852-2862.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA